Patent intelligence · US
US 9254274
Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
Patent details — US 9254274
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 9, 2016
- Expiration
- Feb 4, 2036
- Applicant
- Catalyst Pharmaceuticals, Inc.
- Claims
- 37
- CPC classes
- A61K, A61K31/13, A61K31/131, A61K31/195
Quick answer
US 9254274 (Method of treating Tourette'S disorder with GABA-aminotransferase inactivators) is held by Catalyst Pharmaceuticals, Inc.. Status: granted. Granted Feb 9, 2016. Expires Feb 4, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Catalyst Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 37
- CPC classes
- A61K, A61K31/13, A61K31/131, A61K31/195, A61K31/197, A61P
More from Catalyst Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11806421
Porous-cellulose particles and production method thereof, and cosmetic
granted -
US 11701307
Organic-inorganic composite particles, manufacturing method therefor, and cosmetic
granted -
US 11491212
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
granted -
US 11401513
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 11384062
Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
granted -
US 11266724
Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
granted -
US 11203749
Factor VII polypeptides that are modified and uses thereof
granted -
US 11020326
Hollow particles and cosmetic
granted
Frequently asked questions
What is US patent 9254274?
US 9254274 (Method of treating Tourette'S disorder with GABA-aminotransferase inactivators) is held by Catalyst Pharmaceuticals, Inc.. Status: granted. Granted Feb 9, 2016. Expires Feb 4, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9254274?
Catalyst Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 61 pharmaceutical patents for this assignee.
When does US 9254274 expire?
Our index shows an expiration date of Feb 4, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.